CN106491703A - A kind of Chinese and Western medicine combination for treating infantile viral myocarditis and its preparation method and application - Google Patents
A kind of Chinese and Western medicine combination for treating infantile viral myocarditis and its preparation method and application Download PDFInfo
- Publication number
- CN106491703A CN106491703A CN201611186861.9A CN201611186861A CN106491703A CN 106491703 A CN106491703 A CN 106491703A CN 201611186861 A CN201611186861 A CN 201611186861A CN 106491703 A CN106491703 A CN 106491703A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese
- western medicine
- medicine combination
- viral myocarditis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of Chinese and Western medicine combination for treating infantile viral myocarditis and its preparation method and application, the Chinese and Western medicine combination is made up of the following raw material according to weight portion：11 19 parts of Dioxopromethazine, 8 16 parts of ambroxol, 15 parts of selamectin, 37 parts of peppermint oil.By Dioxopromethazine, ambroxol, selamectin co-grinding, deionized water is added, 70 72 DEG C are warming up to, and 30 35min of stir process, then mix with peppermint oil, ultrasonically treated 18min at a temperature of 63 DEG C, ultrasonic power is 1000W, then stir at a temperature of 65 DEG C to dry obtain final product Chinese and Western medicine combination.The curative effect of present invention treatment infantile viral myocarditis is extremely notable, treatment cycle is short, cure rate up to 94%, can reach treat both principal and secondary aspect of disease, recurrence rate is low and there is immunoregulation effect.Taking convenience of the present invention, composition are simple and easy to get, prepare easy, with low cost, good effect, instant effect, have no toxic side effect, also produce the side effects such as Neuroleptic Leukocytopenia, vascular pain, diarrhoea that other treatment method produces.
Description
Technical field
The present invention relates to pharmaceutical technology field, specifically a kind of Chinese and Western medicine combination for treating infantile viral myocarditis and its
Preparation method and application.
Background technology
Infantile viral myocarditis, virus invade cardiac muscle, cause cardiac muscle cell's denaturation, necrosis and interstitial inflammation, referred to as
Vital myocarditis.Fall ill in recent years and gradually increase, each age falls ill, but common with preschool and school-ager, it is apt to occur in
Summer, autumn.Majority of cases 1～2 week or simultaneously has forerunner's medical history of the infection of the upper respiratory tract or infection of digestive canal before onset.Clinical
Performance weight differs, and the lighter is only showed like " flu " sample, or shows as weak, hidrosis, palpitaition, the discomfort such as uncomfortable in chest.Severe one is quickly
There is the even sudden death of heart failure, cardiogenic shock, severe arrhythmia.
Premorbid had the premonitory symptoms such as the infection of the upper respiratory tract, diarrhoea, vomiting, stomachache, heating in 1～3 week.Subsequently there is face
Color is pale, weak, hidrosis, apocleisis, uncomfortable in chest, Nausea and vomiting, epigastric discomfort；Can there are oedema, shortness of breath, activity during serious symptom
Limited.Burst heart failure, pulmonary edema, severe arrhythmia, cardiogenic shock, cardio-cerebral syndrome.Check infant cardiac size
Normal or increase, increased heart rate or slow down, the dimnition of cardiac sound, first heart sound is low blunt, takes place frequently early rich, or even fetal heart sound or cantering rhythm.
Single cases pareordia can hear I-III grade of systolic murmur, pericardiac friction sound or hydropericardium sign.
Due to the extensive application of antibiotic Chinese and Western medicine combination, rheumatic myocarditis incidence of disease is obvious must to be declined, but
It is that the viral myocarditis incidence of disease but increases.Found according to the research of science, vital myocarditis morbidity can be by the straight of virus
Access is invaded to be caused, or poisoning intrusion body causes immune system to be damaged and caused, morbidity mostly child or adolescent,
In addition spring is the season of virus breeding, prevent myocarditis more should people together vigilant.It is thus desirable to constantly looking for new having
The treatment Chinese and Western medicine combination of effect.
Content of the invention
It is an object of the invention to provide a kind of Chinese and Western medicine combination for treating infantile viral myocarditis and preparation method thereof
And application, to solve the problems, such as to propose in above-mentioned background technology.
For achieving the above object, the present invention provides following technical scheme：
A kind of Chinese and Western medicine combination for treating infantile viral myocarditis, is made up of the following raw material according to weight portion：Gram cough
Quick 11-19 parts, ambroxol 8-16 parts, selamectin 1-5 parts, peppermint oil 3-7 parts.
As further scheme of the invention：The Chinese and Western medicine combination of the treatment infantile viral myocarditis, is pressed by following
Raw material according to weight portion is constituted：Dioxopromethazine 13-17 parts, ambroxol 10-14 parts, selamectin 2-4 parts, peppermint oil 4-6 parts.
As further scheme of the invention：The Chinese and Western medicine combination of the treatment infantile viral myocarditis, is pressed by following
Raw material according to weight portion is constituted：15 parts of Dioxopromethazine, 12 parts of ambroxol, 3 parts of selamectin, 5 parts of peppermint oil.
A kind of preparation method of the Chinese and Western medicine combination for treating infantile viral myocarditis, comprises the steps of：
1) deionized water of 2.8 times of three's mass by Dioxopromethazine, ambroxol, selamectin co-grinding, is added, is warming up to
70-72 DEG C, and stir process 30-35min at such a temperature, mixture A is obtained；
2) mixture A is mixed with peppermint oil, ultrasonically treated 18min at a temperature of 63 DEG C, ultrasonic power is 1000W,
Stirred at a temperature of 65 DEG C to dry again and obtain final product Chinese and Western medicine combination.
As further scheme of the invention：It is warming up to 71 DEG C, and stir process 32min at such a temperature.
Application of the Chinese and Western medicine combination in the Chinese and Western medicine combination for the treatment of infantile viral myocarditis is prepared.
Compared with prior art, the invention has the beneficial effects as follows：
, under the interaction of each raw material, the curative effect for treating infantile viral myocarditis is extremely notable for the present invention, treatment week
Phase is short, cure rate up to 94%, can reach treat both principal and secondary aspect of disease, recurrence rate is low, have no toxic side effect and there is immunoregulation effect, use
In treatment vital myocarditis, particularly infantile viral myocarditis.Chinese and Western medicine administered in combination of the present invention is convenient, and composition is simply easy
, easy, with low cost, good effect, instant effect is prepared, Neuroleptic Leukocytopenia, the blood that other treatment method is produced is not produced yet
The side effects such as pipe pain, diarrhoea.
Specific embodiment
Below in conjunction with the embodiment of the present invention, to the embodiment of the present invention in technical scheme be clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiment.In based on the present invention
Embodiment, the every other embodiment obtained under the premise of creative work is not made by those of ordinary skill in the art, all
Belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, a kind of Chinese and Western medicine combination for treating infantile viral myocarditis, by following according to weight portion
Raw material composition：11 parts of Dioxopromethazine, 8 parts of ambroxol, 1 part of selamectin, 3 parts of peppermint oil.
By Dioxopromethazine, ambroxol, selamectin co-grinding, the deionized water of 2.8 times of three's mass is added, 70 are warming up to
DEG C, and stir process 30min at such a temperature, mixture A is obtained.Mixture A is mixed with peppermint oil, at a temperature of 63 DEG C
Ultrasonically treated 18min, ultrasonic power are 1000W, then stir at a temperature of 65 DEG C to dry obtain final product Chinese and Western medicine combination.
Embodiment 2
In the embodiment of the present invention, a kind of Chinese and Western medicine combination for treating infantile viral myocarditis, by following according to weight portion
Raw material composition：19 parts of Dioxopromethazine, 16 parts of ambroxol, 5 parts of selamectin, 7 parts of peppermint oil.
By Dioxopromethazine, ambroxol, selamectin co-grinding, the deionized water of 2.8 times of three's mass is added, 72 are warming up to
DEG C, and stir process 35min at such a temperature, mixture A is obtained.Mixture A is mixed with peppermint oil, at a temperature of 63 DEG C
Ultrasonically treated 18min, ultrasonic power are 1000W, then stir at a temperature of 65 DEG C to dry obtain final product Chinese and Western medicine combination.
Embodiment 3
In the embodiment of the present invention, a kind of Chinese and Western medicine combination for treating infantile viral myocarditis, by following according to weight portion
Raw material composition：13 parts of Dioxopromethazine, 10 parts of ambroxol, 2 parts of selamectin, 4 parts of peppermint oil.
By Dioxopromethazine, ambroxol, selamectin co-grinding, the deionized water of 2.8 times of three's mass is added, 71 are warming up to
DEG C, and stir process 32min at such a temperature, mixture A is obtained.Mixture A is mixed with peppermint oil, at a temperature of 63 DEG C
Ultrasonically treated 18min, ultrasonic power are 1000W, then stir at a temperature of 65 DEG C to dry obtain final product Chinese and Western medicine combination.
Embodiment 4
In the embodiment of the present invention, a kind of Chinese and Western medicine combination for treating infantile viral myocarditis, by following according to weight portion
Raw material composition：17 parts of Dioxopromethazine, 14 parts of ambroxol, 4 parts of selamectin, 6 parts of peppermint oil.
By Dioxopromethazine, ambroxol, selamectin co-grinding, the deionized water of 2.8 times of three's mass is added, 71 are warming up to
DEG C, and stir process 32min at such a temperature, mixture A is obtained.Mixture A is mixed with peppermint oil, at a temperature of 63 DEG C
Ultrasonically treated 18min, ultrasonic power are 1000W, then stir at a temperature of 65 DEG C to dry obtain final product Chinese and Western medicine combination.
Embodiment 5
In the embodiment of the present invention, a kind of Chinese and Western medicine combination for treating infantile viral myocarditis, by following according to weight portion
Raw material composition：15 parts of Dioxopromethazine, 12 parts of ambroxol, 3 parts of selamectin, 5 parts of peppermint oil.
By Dioxopromethazine, ambroxol, selamectin co-grinding, the deionized water of 2.8 times of three's mass is added, 71 are warming up to
DEG C, and stir process 32min at such a temperature, mixture A is obtained.Mixture A is mixed with peppermint oil, at a temperature of 63 DEG C
Ultrasonically treated 18min, ultrasonic power are 1000W, then stir at a temperature of 65 DEG C to dry obtain final product Chinese and Western medicine combination.
6 toxicity test of embodiment
1) acute toxicity testing：
Application NIH mouse 60, SPF levels, male and female half and half, 18～22g of body weight carry out acute toxicity test.Mouse is random
It is divided into two groups, 30 per group, i.e. control group and administration group, fasting 12 hours before experiment；In prepared by embodiments of the invention 5
Western medicine combination is dissolved in water, (concentration be 6.58g crude drugs/ml, maximum concentration) gavage, and gavage volume is 5ml/kg (i.e. singles
Dosage is 32.9 crude drugs/kg), control group gives normal saline, is administered 2 times within one day, delivery time 6 hours,
Continuous Observation 14 days after administration, and record toxic reaction and the death toll of mouse.Test result indicate that：Compare with control group,
After administration, mouse has no notable difference, tests Continuous Observation 14 days, and mouse systemic situation, diet, drinking-water, body weight increase are just
Often.Mouse oral gavage the present invention Chinese and Western medicine combination LD50 32.9 crude drugs of ＞/kg, daily maximum dosage-feeding be 65.8 crude drugs/
Kg/ days.The Chinese medicine clinical application amount of the present invention is 1.5g crude drugs/day/people, and in terms of 60kg, average dosage is adult's body weight
0.025g crude drugs/kg/ days.Press batheroom scale：It is resistance to that the Chinese and Western medicine of mouse (average weight is in terms of 20g) the oral administration gavage present invention is combined
By 1316 times that amount is quantity.Therefore Chinese and Western medicine of the invention combination acute toxicity is low, clinical application safety.
2) long term toxicity test：
The Chinese and Western medicine combination of the embodiment of the present invention 5 presses 10.78,20.35 and 33.48g crude drugs/kg continuous uses 15 to mouse
After all (1.0ml/100g body weight, daily 2 times) and drug withdrawal 3 weeks, as a result show：Chinese and Western medicine of the present invention combination to the hair of rat,
The indexs such as behavior, stool and urine, body weight, organ weights, blood picture, hepatic and renal function, blood sugar, blood fat have no significant effect, internal organs naked eyes
Do not find that difference change and histological indications show, medication 15 weeks and after being discontinued 3 weeks, each internal organs of rat nothing substantially changes
Become.Illustrate that Chinese and Western medicine of the present invention is combined to small toxicity after rat long-term prescription, also without abnormal reaction, application safety after drug withdrawal.
7 clinical testing of embodiment
1. physical data
Infantile viral myocarditis 50 children, wherein man 25, women 25, age 5-12 year, average 7.1 years old；Disease
Journey 8-42d, average 25d.
2. diagnose and inclusive criteria
Vital myocarditis of the diagnostic criteria with reference to the national heart disease in children science meeting Kunming of in September, 1999 meeting revision
Diagnostic criteria (paediatrics branch of Chinese Medical Association cardiovasology group diagnosis of viral myocarditis standard [J] Pediatrics magazine,
2000,38(2):2).
Inclusive criteria：1) age 5-12 year, receive to take Chinese and Western medicine combination；2) clinical main suit is palpitaition, weak；3) heart
Expand (x-ray, echocardiography have one of performance)；4) ECG change, 2 based on R ripples or more than 2 main
Lead (I, II, aVF, V5) ST-T changes and continues more than 4d with dynamic change, and antrum, atrioventricular block are completely right or left
Bundle-branch block, Cheng Lianlv, many types of, paired or parallel proiosystole, low-voltage (except neonate) and abnormality Q wave；5) enzyme
Learn and check that creatine kinase isozyme (CK-MB) and hydroxybutyric dehydrogenase (HBDH) raise (Beckman full automatic biochemical apparatus speed
Method is detected)；6) etiological diagnosis foundation:Virus is separated to from excrement, throat swab or blood.
Treated using the Chinese and Western medicine combination prepared in embodiment 5, twice daily, oral 0.5g, continuously controls every time
Treat 10 days.
3. observation index
Determine Bardhan indexes before and after treatment (0-3 levels represent that clinical symptoms are nothing, slight, moderate, severe respectively).
4. efficacy assessment standard
Clinical cure：Clinical symptoms, sign all disappear, and electrocardiographic oscillogram observation or continuous more than 2 times electrocardios recover normal,
Myocardial enzymes (CK-MB, HBDH) recover normal.Effective：Palpitaition symptom disappears substantially, and electrocardiographic oscillogram observation or electrocardiogram have changed
Kind, systolia ectopica number reduces >=50%, one when continuing between compared with shortening more than 50% before treatment, or take place frequently and switch to multiple or multiple turn
For accidental, myocardial enzymes (CK-MB, HBDH) reduction.Invalid：Palpitaition symptom and electrocardio ripple or electrocardiogram are unchanged or increase, the heart
Creatase is composed without improvement.
5. result
Before and after treatment, Bardhan indexes are relatively shown in Table 1.
Table 1
| Uncomfortable in chest | Weak | Palpitaition | Shortness of breath | |
| Before treatment | 2.75±0.20 | 2.42±0.11 | 1.85±0.12 | 1.35±0.11 |
| After treatment | 0.92±0.18* | 0.57±0.11* | 0.81±0.15* | 0.70±0.12* |
Note：Compare * P with before same group treatment<0.05.
Before and after treatment, CK-MB and HBDH levels are relatively shown in Table 2.
Table 2
| CK-MB | HBDH | |
| Before treatment | 39.1±1.2 | 265.2±14.8 |
| After treatment | 23.9±1.5* | 175.5±12.0* |
Note：Compare * P with before same group treatment<0.05.
Through treatment, find in 50 patients, clinical cure 47, effective 3, invalid 0.
Model case
Poplar, man, 3 years old, the vital myocarditis that AD causes for the infection of the upper respiratory tract, with uncomfortable in chest, weak, cough
Cough, Electrocardioscopy has arrhythmia cordis to change, and ST sections are moved down, and T ripples are inverted；Myocardium enzyme checks α HBDH, AST, LDH, CKMB and CK
Higher.The Chinese and Western medicine combination prepared using embodiment 5 is treated, and twice a day, each takes 0.5g, continuous treatment 10 days.
The uncomfortable in chest, weak of infant, cough symptom disappear, and infection of the upper respiratory tract illness disappears, and Electrocardioscopy is normal, expand heart and disappear
Lose, myocardial enzymes recover normal.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Contain an independent technical scheme, this narrating mode of specification is only that those skilled in the art should for clarity
Using specification as an entirety, the technical scheme in each embodiment can also form those skilled in the art through appropriately combined
Understandable other embodiment.
Claims (6)
1. a kind of Chinese and Western medicine combination for treating infantile viral myocarditis, it is characterised in that by the following raw material according to weight portion
Composition：Dioxopromethazine 11-19 parts, ambroxol 8-16 parts, selamectin 1-5 parts, peppermint oil 3-7 parts.
2. the Chinese and Western medicine combination for the treatment of infantile viral myocarditis according to claim 1, it is characterised in that pressed by following
Raw material according to weight portion is constituted：Dioxopromethazine 13-17 parts, ambroxol 10-14 parts, selamectin 2-4 parts, peppermint oil 4-6 parts.
3. the Chinese and Western medicine combination for the treatment of infantile viral myocarditis according to claim 1, it is characterised in that pressed by following
Raw material according to weight portion is constituted：15 parts of Dioxopromethazine, 12 parts of ambroxol, 3 parts of selamectin, 5 parts of peppermint oil.
4. the preparation method that a kind of Chinese and Western medicine of the treatment infantile viral myocarditis as described in claim 1-3 is arbitrary is combined,
Characterized in that, comprising the steps of：
1) deionized water of 2.8 times of three's mass by Dioxopromethazine, ambroxol, selamectin co-grinding, is added, 70- is warming up to
72 DEG C, and stir process 30-35min at such a temperature, mixture A is obtained；
2) mixture A is mixed with peppermint oil, ultrasonically treated 18min at a temperature of 63 DEG C, ultrasonic power is 1000W, then
Stir at a temperature of 65 DEG C to dry and obtain final product Chinese and Western medicine combination.
5. the preparation method that the Chinese and Western medicine for the treatment of infantile viral myocarditis according to claim 4 is combined, its feature exist
In being warming up to 71 DEG C, and stir process 32min at such a temperature.
6. the Chinese and Western medicine combination as described in claim 1-3 is arbitrary is in the Chinese and Western medicine combination for the treatment of infantile viral myocarditis is prepared
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611186861.9A CN106491703A (en) | 2016-12-21 | 2016-12-21 | A kind of Chinese and Western medicine combination for treating infantile viral myocarditis and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611186861.9A CN106491703A (en) | 2016-12-21 | 2016-12-21 | A kind of Chinese and Western medicine combination for treating infantile viral myocarditis and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106491703A true CN106491703A (en) | 2017-03-15 |
Family
ID=58333417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611186861.9A Withdrawn CN106491703A (en) | 2016-12-21 | 2016-12-21 | A kind of Chinese and Western medicine combination for treating infantile viral myocarditis and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106491703A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420939A (en) * | 2016-12-21 | 2017-02-22 | 郑州莉迪亚医药科技有限公司 | Drug for treating viral myocarditis of children, and preparation method and application thereof |
| CN106955270A (en) * | 2017-04-14 | 2017-07-18 | 黑龙江中桂制药有限公司 | A kind of ambroxol hydrochloride oral solution and preparation method thereof and new application |
-
2016
- 2016-12-21 CN CN201611186861.9A patent/CN106491703A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420939A (en) * | 2016-12-21 | 2017-02-22 | 郑州莉迪亚医药科技有限公司 | Drug for treating viral myocarditis of children, and preparation method and application thereof |
| CN106955270A (en) * | 2017-04-14 | 2017-07-18 | 黑龙江中桂制药有限公司 | A kind of ambroxol hydrochloride oral solution and preparation method thereof and new application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guy et al. | A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215) | |
| Williams et al. | Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes | |
| Höhn et al. | History of dietary treatment from Wilder's hypothesis to the first open studies in the 1920s | |
| Nierenberg et al. | Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome | |
| TWI583390B (en) | Ellagitannins rich extracts composition | |
| Pashankar et al. | Long-term Efficacy of Polyethylene Glycol 3350 for the Treatment of Chroni Constipation in Children with and without Encopresis | |
| Patel et al. | How much is too much? Exploring pseudohyperaldosteronism in glycyrrhizic acid toxicity from chronic licorice root consumption | |
| CN106491703A (en) | A kind of Chinese and Western medicine combination for treating infantile viral myocarditis and its preparation method and application | |
| Cochran et al. | Pediatric hyperglycemic hyperosmolar syndrome: diagnostic difficulties and high mortality rate | |
| Umez-Eronini et al. | Chloroquine induced involuntary movements. | |
| CN107624068B (en) | Compositions comprising cinnamaldehyde and zinc and methods of using such compositions | |
| CN106822231A (en) | Biological bacterium solution with function of blood sugar reduction and preparation method thereof | |
| Aziz et al. | Prevalence and awareness of cardiovascular disease including life styles in a lower middle class urban community in an Asian country | |
| CN106470691A (en) | Comprise cinnamic aldehyde and the compositionss of zinc and the using method of such composition | |
| KR100880537B1 (en) | Composition comprising cantaloupe melon extract and gliadin for improving ability of brain | |
| CN106511458A (en) | Chinese and western medicine composition for treating pediatric viral myocarditis | |
| CN106727921A (en) | A kind of medicine for treating infantile viral myocarditis | |
| CN107233432A (en) | It is a kind of that pharmaceutical composition, preparation of liver function and preparation method thereof are protected with reducing pressure and sugar | |
| CN106474198A (en) | A kind of treat medicine of infantile viral myocarditis and its preparation method and application | |
| CN105616581A (en) | Glipizide-containing pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN106420939A (en) | Drug for treating viral myocarditis of children, and preparation method and application thereof | |
| CN115068570B (en) | Li medicine composition for dispelling effects of alcohol and protecting liver as well as preparation method and application thereof | |
| JPS59132884A (en) | Composition for promoting propagation of bifidobacterium | |
| Padilla | Obesity, Muscle Function, And Anthropometric Measures In F344 Rat Model During Aging: 3092 | |
| Galimov | MODERN UNDERSTANDINGOFTHE MANAGEMENT OF PATIENTS WITH DIABETES MELLITUS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170315 |